Embecta Corp Stock Price, News & Analysis

Embecta Corp. (NASDAQ: EMBC) reported its Q2 FY2025 financial results with revenues of $259.0 million, down 9.8% from the previous year. The company saw a decrease in both U.S. revenues (-8.4%) and international revenues (-11.3%). Despite revenue challenges, profitability metrics improved with adjusted operating income margin increasing to 31.4% from 26.1% and adjusted EBITDA margin rising to 37.5% from 31.6%. Adjusted earnings per share reached $0.70, up from $0.67. The company announced a quarterly dividend of $0.15 per share and reduced debt by paying down approximately $27.4 million. For FY2025, Embecta updated its guidance, projecting revenues between $1,073-$1,090 million and maintaining adjusted EPS guidance of $2.70-$2.90 despite lowered revenue expectations.

Embecta (Nasdaq: EMBC) has announced its Board of Directors has declared a quarterly cash dividend of $0.15 per share for all outstanding common stock. The dividend will be paid on June 13, 2025 to stockholders who are on record as of the close of business on May 28, 2025.

Embecta (Nasdaq: EMBC), a global diabetes care company specializing in insulin delivery, has announced its upcoming Analyst and Investor Day scheduled for May 22, 2025, from 9:00 a.m. to 12:30 p.m. in New York City.

The event will feature presentations from President & CEO Dev Kurdikar, CFO Jake Elguicze, and other leadership team members. They will discuss:

• Strategic and business overview
• Value creation opportunities
• Company's financial profile
• Long-term objectives

While in-person attendance is by invitation only, interested parties can participate via webcast through InvestorDay.embecta.com. A replay and presentation materials will be available in the 'Events & Presentations' section of the company's Investor Relations website after the event.

Embecta (Nasdaq: EMBC), a global diabetes care company specializing in insulin delivery, has announced it will host a conference call to discuss its fiscal second quarter 2025 financial results on Friday, May 9, 2025, at 8:00 a.m. Eastern Time.

The company will provide an operational update and conduct a question and answer session during the call. Interested parties can access the live webcast through the company's investor relations website at investors.embecta.com. A replay of the webcast will be available from 11:00 a.m. ET on the same day and will remain archived on the website for one year.

Embecta (EMBC) announced the publication of new global insulin injection recommendations in the Mayo Clinic Proceedings, marking the first major update in nearly 10 years. The FITTER Forward Expert Recommendations, authored by 16 diabetes specialists from 13 countries, aims to enhance clinical outcomes for diabetes patients worldwide through improved insulin injection techniques.

The recommendations focus on several key areas including: new insights on injection device technology, standardized injection techniques to prevent complications, structured training programs for healthcare providers, and patient-centered recommendations to improve therapy adherence. Led by Dr. David Klonoff, the initiative emphasizes the critical importance of proper insulin administration techniques in maintaining target blood glucose levels.

Embecta will host a webinar on April 8, 2025, at 12 pm EST featuring FITTER Forward authors to discuss the new recommendations and their clinical impact.

Embecta (Nasdaq: EMBC) has announced its participation in the upcoming J.P. Morgan Global Leveraged Finance Conference in Miami. The company's Chief Financial Officer, Jake Elguicze, is scheduled to deliver a presentation on Tuesday, February 25, 2025, at 3:00 p.m. ET.

Embecta Corp. (EMBC) reported Q1 FY2025 financial results with revenues of $261.9 million, down 5.6% on a reported basis. The company experienced declines in both U.S. (down 4.6%) and International revenues (down 6.6%). Adjusted earnings per diluted share were $0.65, compared to $0.61 in the prior year period.

The company is updating its FY2025 guidance, adjusting revenue outlook due to foreign exchange assumptions while raising expectations for certain key financial metrics. The restructuring plan related to the discontinuation of the insulin patch pump program remains on track for completion by the end of H1 FY2025.

Key financial metrics include adjusted EBITDA of $97.3 million with a 37.2% margin, and the declaration of a $0.15 per share quarterly dividend. The company maintains strong liquidity with $216.7 million in cash and equivalents, while managing $1.569 billion in debt principal.

Embecta (Nasdaq: EMBC) has announced that its Board of Directors has declared a quarterly cash dividend of $0.15 per share for each issued and outstanding share of the company's common stock. The dividend will be paid on March 14, 2025, to stockholders who are on record at the close of business on February 28, 2025.

Embecta (Nasdaq: EMBC), a global diabetes care company specializing in insulin delivery, has announced it will host a conference call to discuss its fiscal first quarter 2025 financial results on Thursday, February 6, 2025, at 8:00 a.m. Eastern Time. The event will include an operational update and a Q&A session.

Participants can access the live webcast through the company's investor relations website at investors.embecta.com. A replay of the webcast will be available starting at 11:00 a.m. ET on the same day and will remain accessible on the website for one year.